NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Tandem Diabetes Care, Inc. TNDM
14 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.0B
▲ 7.9% vs FY2024
EPS · FY25
$-3.04
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-97.9%
Net margin · FY25
-20.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.0B
Revenue, FY2025 · full 14-year series below
Revenue
Net income
The company lost 20 cents on every revenue dollar this year.
Per share
USD -3.04
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-97.9%
Return on equity, FY2025
ROE
Operating margin-18.5%
Net margin-20.2%
Return on assets-22.1%
Each USD of equity lost 98 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 0.00
Share of profit-0.0%
Consecutive raises—
Growth
+15.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+8.2%
+15.3%
+30.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years+9.6%
Change, 10 years—
The share count grew 10% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 881.1M
total assets, end of FY2025
Total assetsUSD 881.1M
EquityUSD 155.2M
CashUSD 90.6M
Gross debtUSD 310.0M
Net debtUSD 219.4M
Current ratio2.55×
Net debt stands at 141% of equity.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
Revenue $B
1.0
0.9
0.7
0.8
0.7
0.5
0.4
0.2
0.1
0.1
0.1
0.0
0.0
0.0
Operating income $B
−0.2
−0.1
−0.2
−0.1
0.0
−0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
EBITDA $B
−0.2
−0.1
−0.2
−0.1
0.0
0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
·
·
Net income $B
−0.2
−0.1
−0.2
−0.1
0.0
−0.0
−0.0
−0.1
−0.1
−0.1
−0.1
−0.1
−0.1
−0.0
EPS, diluted $
−3.04
−1.47
−3.43
−1.47
0.24
−0.56
−0.42
−2.55
−12.87
−27.30
−25.04
−3.42
−21.46
−175.88
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−97.9
−33.3
−59.1
−21.7
3.9
−12.3
−15.2
−240.1
·
−290.0
−122.7
−93.5
−1331.3
·
Shares out B
0.07
0.07
0.07
0.06
0.06
0.06
0.06
0.06
0.01
0.00
0.03
0.02
0.02
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
54 of 54
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed